Large study finds no evidence cannabis treats anxiety, depression or PTSD

A major review published in The Lancet Psychiatry concludes that medicinal cannabis does not effectively treat anxiety, depression or post-traumatic stress disorder. The analysis of 54 randomized controlled trials over 45 years found limited evidence for other conditions like insomnia and autism. Researchers warn of potential harms including psychosis risk and delayed effective treatments.

The largest review to date on cannabinoids for mental health conditions, published in The Lancet Psychiatry, reports no effective treatment for anxiety, depression or PTSD. Led by Dr. Jack Wilson from the University of Sydney's Matilda Centre, the study examined safety and effectiveness across various disorders using data from 54 randomized controlled trials spanning 1980 to 2025. About 27 percent of people aged 16-65 in the United States and Canada report medical cannabis use, with half citing mental health symptoms as the reason. Dr. Wilson stated, 'Though our paper didn't specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments.' Limited indications of benefit appeared for cannabis use disorder, autism, insomnia and tics or Tourette's syndrome, though evidence quality remains low. Dr. Wilson noted, 'In the absence of robust medical or counseling support, the use of medicinal cannabis in these cases are rarely justified.' For substance use disorders, cannabis-based treatments showed potential for cannabis dependence when combined with psychological therapy, but increased cravings in cocaine-use disorder cases. The review confirms benefits for epilepsy-related seizures, multiple sclerosis spasticity and certain pain types, but not mental health. Funded by the NHMRC, the findings support evidence-based clinical decisions amid rising medicinal cannabis use and calls for stricter regulation from groups like the American Medical Association.

Related Articles

Young adult woman in bed using cannabis vape as sleep aid at night, with study elements, for news illustration.
Image generated by AI

Many young adults use cannabis as a sleep aid, study finds

Reported by AI Image generated by AI Fact checked

A national study of U.S. young adults ages 19 to 30 found that about 22% reported using cannabis, alcohol, or both to help themselves fall asleep, with cannabis far more common than alcohol. Researchers warn that while these substances may help people drift off, frequent use could worsen sleep over time and raise the risk of substance use problems.

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

Reported by AI

In the latest assessment following prior reviews like the 2025 Annals analysis showing limited THC benefits, a Cochrane review finds cannabis-based medicines offer no clinically meaningful relief for chronic neuropathic pain versus placebo. Analyzing 21 randomized trials with over 2,100 adults, it reports no high-quality evidence of effectiveness, with only minor, insignificant improvements from THC-CBD combinations.

A University at Buffalo study indicates that cannabis-infused beverages may help reduce alcohol consumption among users. Survey participants who switched to these drinks reported cutting their weekly alcohol intake nearly in half. Nearly two-thirds of respondents said they reduced or stopped drinking alcohol after starting cannabis beverages.

Reported by AI

A small clinical trial has found that a single dose of the psychedelic drug dimethyltryptamine (DMT) led to rapid and sustained reductions in depression symptoms when combined with therapy. Participants experienced improvements lasting up to six months, with mild side effects reported. The study highlights potential benefits of short-acting psychedelics for treatment-resistant depression.

Researchers report designing and testing five fluorinated, reversible carbamate derivatives of psilocin—psilocybin’s active metabolite—aimed at reducing acute psychedelic-like effects while preserving key serotonin-receptor activity. In experiments in mice, a lead compound labeled 4e produced lower but longer-lasting brain exposure to psilocin-related activity and triggered fewer head-twitch responses than pharmaceutical-grade psilocybin, according to a study in the Journal of Medicinal Chemistry.

Reported by AI

A revised ordinance will ban consumer products containing cannabis-derived CBN starting in June. Only patients with specific conditions, such as intractable diseases without alternative treatments, will be allowed to use them.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline